ReNeuron Group to begin stem cell treatment of critical limb ischaemia

ReNeuron Group has received regulatory approval to begin the first phase of a clinical trial in the UK for the company's ReN009 stem cell therapy treatment for critical limb ischaemia.

ReNeuron Group has received regulatory approval to begin the first phase of a clinical trial in the UK for the company's ReN009 stem cell therapy treatment for critical limb ischaemia.

Critical limb ischaemia, a condition which leads to blood vessel blockage in limbs such as toes and can lead to amputation, is ReNeuron's second major disease target after stroke in its CTX stem cell line.

The stem cell therapeutics group said ReN009 has the potential to restore sufficient blood flow in the affected lower limb of patients with the condition.

The Phase 1 clinical trial will be undertaken though NHS Tayside at Ninewells Hospital and Medical School in Dundee, Scotland.

ReN009 cells will be administered via straightforward intramuscular injection into the affected lower limb of nine patients with peripheral arterial disease.

ReNeuron was recently awarded a late stage biomedical catalyst grant of £0.4m from the Technology Strategy Board, the UK Government's innovation agency, to be deployed towards the cost of the study.

"These clinical trial approvals for our next major disease target, together with the recently announced biomedical catalyst funding for the Phase I critical limb ischaemia study, represent strong endorsements of the strength of ReNeuron's technologies and its CTX stem cell therapy candidate," said Chief Executive Officer Michael Hunt.

Shares climbed 1.94% to 3.15p at 10:08 Tuesday.

RD

Recommended

Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020
Why investors should be “cautiously bullish” for 2020
Stockmarkets

Why investors should be “cautiously bullish” for 2020

Analysts have been out in force making rosy predictions for stockmarkets in 2020, but while there is certainly a case for optimism, investors should r…
17 Jan 2020

Most Popular

Of course bitcoin is a bubble – a bubble you can’t ignore
Bitcoin

Of course bitcoin is a bubble – a bubble you can’t ignore

Bitcoin’s wild ride is being called a bubble by many. And it is, says Dominic Frisby. But that’s not necessarily a bad thing. And it’s a bubble in whi…
13 Jan 2021
A simple way to profit from the next big trend change in the markets
Investment strategy

A simple way to profit from the next big trend change in the markets

Change is coming to the markets as the tech-stock bull market of the 2010s is replaced by a new cycle of rising commodity prices. John Stepek explains…
14 Jan 2021
I wish I knew what a SPAC was, but I’m too embarrassed to ask
Too embarrassed to ask

I wish I knew what a SPAC was, but I’m too embarrassed to ask

A financial instrument called a “special purpose acquisition company”, or SPAC for short, is growing increasingly popular in the US stockmarkets. But …
12 Jan 2021